Shrestha Shakti, Poudel Arjun, Steadman Kathryn J, Nissen Lisa M
School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia
School of Clinical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.
BMJ Open. 2021 Apr 1;11(4):e043766. doi: 10.1136/bmjopen-2020-043766.
Making a meaningful decision on deprescribing of potentially inappropriate medications in older adults with life-limiting illnesses (LLIs) and limited life expectancy (LLE) is often challenging. Therefore, we aimed to elicit opinion and gain consensus on a deprescribing tool for use in this population.
A modified-Delphi method will be used to obtain a consensus from a panel of experts in geriatric therapeutics on a deprescribing tool for use in people aged ≥65 years with LLIs and LLE. Through an online survey, in the initial round, the panel will anonymously elicit their opinion on a series of items related to the conceptual model of the deprescribing tool, its practicality and deprescribing of medications, while on the controlled feedback in subsequent rounds till a consensus is reached or the panellists stop revising their answers. In each round, panel members will be using a 5-point Likert scale to rate their agreement with the statement. Consensus will be considered on ≥75% of agreement on the statements.
All the participants will receive an invitation and participant information but they need to consent for the participation. Ethics approval has been granted from the University of Queensland Health and Behavioural Sciences, Low and Negligible Risk Ethics Sub-Committee (reference: 2020001069). The results of this project will be disseminated through conferences and a peer-reviewed clinical journal.
对于患有生命有限疾病（LLI）且预期寿命有限（LLE）的老年人，就停用潜在不适当药物做出有意义的决定通常具有挑战性。因此，我们旨在就一种用于该人群的停药工具征求意见并达成共识。
将采用改良德尔菲法，从老年治疗学专家小组中就一种用于≥65岁患有LLI和LLE的人群的停药工具达成共识。通过在线调查，在第一轮中，专家小组将匿名征求他们对与停药工具的概念模型、实用性和药物停用相关的一系列项目的意见，而在后续轮次的控制反馈中，直到达成共识或小组成员停止修改他们的答案。在每一轮中，小组成员将使用5点李克特量表对他们对陈述的同意程度进行评分。当对陈述的同意率≥75%时，将视为达成共识。
所有参与者将收到邀请和参与者信息，但他们需要同意参与。已获得昆士兰大学健康与行为科学学院低风险和可忽略风险伦理小组委员会的伦理批准（参考号：2020001069）。该项目的结果将通过会议和同行评审的临床杂志进行传播。
